← Who reports today · Health Care
JNJ · Q2 2026
Archived report (Q2 2026). Latest deep dive →
US GAAP · $M · vs Q2 2025 · reported 07/15/2026
JNJ — Johnson & Johnson develops and manufactures healthcare products across pharmaceuticals, medical devices, and consumer health.
More about the company
Based in New Brunswick, New Jersey, it operates worldwide with a broad portfolio of medical and health solutions.
All figures in $M.
Revenue
$25,310
+6.6%
Gross profit
$17,259
+7.1%
68.2% margin
Operating income
$6,747
26.7% margin
Net income
$5,534
-0.1%
$2.27 diluted EPS
Verdict: a solid quarter with reported sales up 6.6% to $25.3B led by Innovative Medicine's 7.8% growth (DARZALEX, CARVYKTI, TREMFYA offsetting STELARA erosion), but GAAP net earnings were flat y/y at $5.5B as higher operating costs and below-the-line items offset gross margin gains, while adjusted EPS rose 4.7% and guidance was raised.
Free cash flow ≈$8.7B (YTD, vs $6.2B prior); adjusted net earnings $7,081M (+5.7%); adjusted EPS $2.90 (+4.7%); FY2026 guidance raised to ~$101.1B reported sales and $11.68 adjusted EPS midpoint.
Source and notation
* marks non-cash / ≈ estimated. Source: Johnson & Johnson press release / 10-Q (SEC EDGAR).
Open the chart as a PNG image ↗ · for sharing and presentations · free to reuse, CC BY 4.0
How this page was made: the figures come from the company's own report on SEC EDGAR; the summary and nuances were drafted by our model from that report; the short company description was also written by our model. Figures checked against the filing on 08/25/2026. How we make the breakdowns · Report an error
More reports: LLY · Q2 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q2 2026 · PFE · Q2 2026 · REGN · Q2 2026 · SYK · Q2 2026 · TMO · Q2 2026 · UNH · Q3 2026 · VRTX · Q2 2026 · all reports